替格瑞洛与阿司匹林对动脉粥样硬化性脑卒中患者神经功能及复发的影响-现代医学

替格瑞洛与阿司匹林对动脉粥样硬化性脑卒中患者神经功能及复发的影响

单位：1. 陕西中医药大学, 陕西咸阳 712046;
2. 宝鸡高新人民医院神经内科, 陕西宝鸡 721000;
3. 宝鸡高新人民医院检验科, 陕西宝鸡 721000

分类号：R743.3

出版年·卷·期（页码）：2018·46·第二期（116-120）

摘要：

目的：观察替格瑞洛与阿司匹林对动脉粥样硬化性脑卒中后神经功能及复发的影响。方法：选取2016年6月至2017年6月在我院住院的符合实验条件的368例脑卒中患者，按照随机数字表法随机分为观察组及对照组，各184例，在发病24 h内，观察组给予替格瑞洛（第1 d负荷量180 mg，第2 d至180 d内90 mg·次^-1，2次·d^-1），对照组给予阿司匹林（第1 d负荷量300 mg，第2~180 d内100 mg·次^-1，1次·d^-1）治疗。比较两组患者发病后1个月、3个月、6个月神经功能恢复情况及复发的发生情况。结果：在发病1月后、3月后及6个月观察组的NIHSS评分较对照组相比明显降低，而复发的发生较对照组明显较少，有统计学意义（P < 0.05）。在整个实验过程中，观察组失访3人，对照组失访1人，其他患者均获得有效随访。随访时间（6.38±1.20）个月。结论：较阿司匹林而言，替格瑞洛在改善动脉粥样硬化性脑卒中后神经功能及复发方面作用更明显，且在不增加副作用的前提下有效的降低患者短期内复发的发生率，其确切的疗效及良好的安全性值得临床进一步推广。

Objective: To observe the effects of ticagrelor and aspirin on neurological function and recurrence after atherosclerotic stroke. Methods: A total of 368 stroke patients who were enrolled in our hospital from June 2016 to June 2017 were selected. According to the random number table method, the patients were randomly divided into observation group and control group, 184 in each, The control group received Ticagrelor (the first day load of 180 mg, the second day to 180th day 90 mg·time^-1, 2 times·d^-1), the control group given aspirin (the first day load of 300 mg, the second-180th day 100 mg·time^-1, 1 times·d^-1) treatment. The recovery of neurological function and the recurrence were observed at 1 month, 3 months, and 6 months after the onset of the two groups. Results: The NIHSS score of the observation group was significantly lower than that of the control group after 1 month, 3 months and 6 months, and the incidence of recurrence was significantly lower than that of the control group (P<0.05). During the whole experiment, the observation group lost 3 people, the control group lost 1 person, while other patients were effectively followed-up. Follow-up time (lasted 6.38±1.20) months. Conclusion: Compared with aspirin, Ticagrelor is more effective in improving neurological function and avoiding relapse after atherosclerotic stroke, and it is effective to reduce the recurrence rate of short-term recurrence without increasing the side effect. The efficacy and good safety is worthy of further clinical further promotion.

参考文献：

[1] RIVERA J,LOZANO M L,NAVARRO N L,et al.Platelet receptors and signaling in the dynamics of thrombus formation[J].Haematologica,2009,94(5):700.
[2] YUSUF S,ZHAO F,M EHTA S R,et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST -segment elevation[J].N Engl J M ed,2001,345(7):494-502.
[3] 中华医学会神经病学分会.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.
[4] BROTT T,ADAMS HP Jr,OLINGER CP,et al.Measurements of acute cerebral infarction:A elinical examination scale[J].Stroke,1989,20(7):864-870.
[5] KASNER S E.Clinical interpretation and use of stroke scales[J].Lancet Neurol,2006,5(7):603.
[6] ADAMS H P,DAVIS P H,LEIRA E C,et al.Baseline NIH stroke scale score strongly predicts outcome after stroke A report of the trial of org 10172 in acute stroke treatment (TOAST)[J].Neurology,1999,53(1):126.
[7] YOUNG F B,WEIR C J,LEES K R.Comparison of the national institutes of health stroke scale with disability outcome measures in acute stroke trials[J].Stroke,2005,36(10):2187.
[8] 陈竺.全国第三次死因回顾抽样调查报告[M].北京:中国协和医科大学出版社,2008.
[9] DONNAN G A,FISHER M,MACLEOD M,et al.Stroke[J].Lancet,2008,371(9624):1612-1623.
[10] Rosamond.Heart disease and stroke statistics-2007 Update:A report from the American heart association statistics committee and stroke statistics subcommittee (vol 115,2007)[J].Circulation,2010,122(1):E9-E9.
[11] 国家卫生计生委防治工程委员会.中国卒中流行报告2015[M].北京:中国协和医科大学出版社,2015.
[12] JOHNSTON S C.Clinical practice.Transient ischemic attack[J].New Engl J Med,2002,347(21):1687.
[13] ROTHWELL P M,GILES M F,CHANDRATHEVA A,et al.Early use of existing preventive strategies for stroke (EXPRESS) study.Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study):a prospective population-based sequential comparison[J].Lancet,2007,370(9596):1432.
[14] WANG Y,WANG Y,ZHAO X,et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.[J].Circulation,2015,132(1):40.
[15] JOHNSTON S C,EASTON J D,FARRANT M,et al.Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial:rationale and design[J].Int J Stroke,2013,8(6):479.
[16] SANDSET E C,BATH P M,BOYSEN G,et al.The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST):a randomised,placebo-controlled,double-blind trial.[J].Lancet,2011,377(9767):741.
[17] No authors.The International Stroke Trial (IST):a randomised trial of aspirin,subcutaneous heparin,both,or neither among 19435 patients with acute ischaemic stroke.International Stroke Trial Collaborative Group.[J].Lancet,1997,349(9065):1569.
[18] CHEN Z M.CAST:randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke[J].Lancet,1997,349(9066):1641.
[19] LIBBY P.Mechanisms of acute coronary syndromes and their implications for therapy[J].New Engl J Med,2013,368(21):2004-13.
[20] KERNAN W N,OVBIAGELE B,BLACK H R et al.Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack:A guideline for healthcare professionals from the American heart association/American stroke association[J].Stroke,2014,45:2160-2236.
[21] RAJU N C,EIKELBOOM J W,HIRSH J.Platelet ADP-receptor antagonists for cardiovascular disease:past,present and future[J].Nat Clin Pract Card,2008,5(12):766-780.
[22] HUSTED S,EMANUELSSON H,HEPTINSTALL S,et al.Pharmacodynamics,pharmacokinetics,and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:a double-blind comparison to clopidogrel with aspirin[J].Eur Herat J,2006,27(9):1038.
[23] STOREY R F,HUSTED S,HARRINGTON R A,et al.Inhibition of platelet aggregation by AZD6140,a reversible oral P2Y12 receptor antagonist,compared with clopidogrel in patients with acute coronary syndromes[J].J Am Coll Cardiol,2007,50(19):1852.
[24] STEINHUBL S,ROE M T.Optimizing platelet P2Y 12,inhibition for patients undergoing PCI[J].Cardiovasc Ther,2007,25(2):188-203.
[25] GIEZEN J J J V,NILSSON L,BERNTSSON P,et al.Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation[J].J Thromb Thrombolys,2009,7(9):1556-1565.
[26] JAMES S,BUDAJ A,AYLWARD P,et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function:results from the platelet inhibition and patient outcomes (PLATO) trial[J].Circulation,2010,122(11):1056.
[27] KOHLI P,WALLENTIN L,REYES E,et al.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study[J].Circulation,2013,127(6):673.
[28] PRICE M J,CLAVIJO L,ANGIOLILLO D J,et al.A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease[J].J Thromb Thrombolys,2015,39(1):8-14.
[29] WALLENTIN L,BECKER R C,BUDAJ A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].New Engl J Med,2009,361(11):1045-1057.
[30] JOHNSTON S C,AMARENCO P,ALBERS G W,et al.Ticagrelor versus aspirin in acute stroke or transient ischemic attack[J].New Engl J Med,2016,375(1):35-43.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录